Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs